Our priority is to acquire speciality drugmakers in the US: Nilesh Gupta

Interview with the managing director of Lupin

Lupin, the pharmaceuticals major, is looking for acquisition up to $1 billion, Managing Director Nilesh Gupta tells Abhineet Kumar & Aneesh Phadnis. Edited excerpts:

Lupin wanted to reach a $5 billion annual turnover by 2017-18, then reduced the target to $3.5 bn. Is it on track?

I think we will fall short of that number. For FY17, we will be roughly $2.5 bn. There was always an inorganic component built in that aspiration, particularly in speciality (pharma). We are still aggressively looking for that but not stupidly. But, we should be north of $3 bn, in any case.

What about